Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 101 UK neurodegenerative disease companies below.
Single-molecule counting point-of-care diagnostics for cardiac and other biomarkers
Psyros Diagnostics develops a point-of-care diagnostic system using single-molecule counting technology to measure biomarkers at extremely low concentrations within around ten…
Specialist CRO for rare disease drug development and commercialisation
TMC Pharma Services is a contract research organisation specialising in drug development support for rare and orphan diseases. The company serves small and mid-sized biotech and…
Convection enhanced delivery consulting and devices for CNS therapeutics
Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and…
Contract proteomics CRO and inventor of TMT isobaric mass tags
Proteome Sciences is a contract proteomics organisation and reagent manufacturer specialising in mass spectrometry-based protein biomarker discovery, validation, and targeted…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company…
AI and photonics platform for personalised drug development
iLoF is a digital health company developing an AI-powered platform that uses proprietary photonics technology to generate optical fingerprints from blood samples, building a…
NLRP3 inflammasome inhibitors for chronic inflammatory disease
NodThera is a clinical-stage biotechnology company developing potent and selective small molecule inhibitors of the NLRP3 inflammasome for diseases driven by chronic inflammation.…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses…
AI genomics for drug target discovery
OutSee is a genomics and drug discovery company using proprietary AI technology to identify and validate novel therapeutic targets. Its core platform applies predictive algorithms…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The…
Europe's largest biomedical discovery institute researching the biology of disease
The Francis Crick Institute is a biomedical discovery institute researching the biology underlying human health and disease. The Institute studies biology from molecules to entire…
Therapeutics targeting lysosomal dysfunction in neurodegeneration
Endlyz Therapeutics is a preclinical-stage biotechnology company developing small molecule modulators to restore endo-lysosomal function in Parkinson's disease and related…